These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 10671640)

  • 21. Pharmacogenetics of antidepressants: clinical aspects.
    Bertilsson L; Dahl ML; Tybring G
    Acta Psychiatr Scand Suppl; 1997; 391():14-21. PubMed ID: 9265947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic differences in drug disposition.
    May DG
    J Clin Pharmacol; 1994 Sep; 34(9):881-97. PubMed ID: 7983231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands.
    Kaneko A; Lum JK; Yaviong L; Takahashi N; Ishizaki T; Bertilsson L; Kobayakawa T; Björkman A
    Pharmacogenetics; 1999 Oct; 9(5):581-90. PubMed ID: 10591538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system.
    Ingelman-Sundberg M; Sim SC
    Biochem Biophys Res Commun; 2010 May; 396(1):90-4. PubMed ID: 20494117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The CYP2C19 enzyme polymorphism.
    Wedlund PJ
    Pharmacology; 2000 Sep; 61(3):174-83. PubMed ID: 10971203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations.
    Kaneko A; Bergqvist Y; Taleo G; Kobayakawa T; Ishizaki T; Björkman A
    Pharmacogenetics; 1999 Jun; 9(3):317-26. PubMed ID: 10471063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects.
    Matimba A; Del-Favero J; Van Broeckhoven C; Masimirembwa C
    Hum Genomics; 2009 Jan; 3(2):169-90. PubMed ID: 19164093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study.
    Balian JD; Sukhova N; Harris JW; Hewett J; Pickle L; Goldstein JA; Woosley RL; Flockhart DA
    Clin Pharmacol Ther; 1995 Jun; 57(6):662-9. PubMed ID: 7781266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele.
    Xiao ZS; Goldstein JA; Xie HG; Blaisdell J; Wang W; Jiang CH; Yan FX; He N; Huang SL; Xu ZH; Zhou HH
    J Pharmacol Exp Ther; 1997 Apr; 281(1):604-9. PubMed ID: 9103550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic polymorphism of drug metabolising enzymes in African populations: implications for the use of neuroleptics and antidepressants.
    Masimirembwa CM; Hasler JA
    Brain Res Bull; 1997; 44(5):561-71. PubMed ID: 9365799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population.
    de Morais SM; Goldstein JA; Xie HG; Huang SL; Lu YQ; Xia H; Xiao ZS; Ile N; Zhou HH
    Clin Pharmacol Ther; 1995 Oct; 58(4):404-11. PubMed ID: 7586932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increasing relevance of pharmacogenetics of drug metabolism in clinical practice.
    Pillans PI
    Intern Med J; 2001 Nov; 31(8):476-8. PubMed ID: 11720061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe.
    Masimirembwa C; Bertilsson L; Johansson I; Hasler JA; Ingelman-Sundberg M
    Clin Pharmacol Ther; 1995 Jun; 57(6):656-61. PubMed ID: 7781265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Interindividual differences in efficacy and toxicity induced by therapeutic drugs and xenobiotics in relation to genetic polymorphisms in xenobiotic metabolizing enzymes].
    Ozawa S
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 1998; (116):69-81. PubMed ID: 10097514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polymorphic drug metabolism.
    Relling MV
    Clin Pharm; 1989 Dec; 8(12):852-63. PubMed ID: 2689060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Role of pharmacogenetics in psychopharmacotherapy].
    Gram LF
    Encephale; 1991; 17 Spec No 1():123-5. PubMed ID: 1864259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interethnic differences of drug-metabolizing enzymes.
    Gaedigk A
    Int J Clin Pharmacol Ther; 2000 Feb; 38(2):61-8. PubMed ID: 10706192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Advances in the study of pharmacogenetics in China in 1996].
    Xie H; Zhou H
    Zhonghua Yi Xue Za Zhi; 1997 Jan; 77(1):77-8. PubMed ID: 9596985
    [No Abstract]   [Full Text] [Related]  

  • 39. Influence of pharmacogenetics on drug disposition and response.
    Eichelbaum M; Evert B
    Clin Exp Pharmacol Physiol; 1996; 23(10-11):983-5. PubMed ID: 8911746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. pNAT and CYP2D6 gene polymorphism in epileptic patients.
    Borlak JT; Harsany V; Schneble H; Haegele KD
    Biochem Pharmacol; 1994 Nov; 48(9):1717-20. PubMed ID: 7980640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.